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Abstract
Background: The use of genome-wide (whole genome or exome) sequencing for population-based newborn
screening presents an opportunity to detect and treat or prevent many more serious early-onset health conditions
than is possible today.
Methods: The Paediatric Task Team of the Global Alliance for Genomics and Health’s Regulatory and Ethics
Working Group reviewed current understanding and concerns regarding the use of genomic technologies for
population-based newborn screening and developed, by consensus, eight recommendations for clinicians, clinical
laboratory scientists, and policy makers.
Results: Before genome-wide sequencing can be implemented in newborn screening programs, its clinical utility
and cost-effectiveness must be demonstrated, and the ability to distinguish disease-causing and benign variants of
all genes screened must be established. In addition, each jurisdiction needs to resolve ethical and policy issues
regarding the disclosure of incidental or secondary findings to families and ownership, appropriate storage and
sharing of genomic data.
Conclusion: The best interests of children should be the basis for all decisions regarding the implementation of
genomic newborn screening.
Keywords: Newborn Screening, Whole Genome Sequencing, Exome Sequencing, Public Policy, Ethics,
Public Health Genetics
Background
The Global Alliance for Genomics and Health is an inter-
national collaboration of more than 400 healthcare, re-
search, disease advocacy, life science, and information
technology institutions working together to promote
human health through sharing of genomic and clinical data
[http://genomicsandhealth.org/]. Within this remit, the
Paediatric Task Team of the Global Alliance’s Regulatory
and Ethics Working Group [http://genomicsandhealth.org/
working-groups/regulatory-and-ethics-working-group] was
established to address issues of particular relevance to
child health.
Recent research has demonstrated that genomic
technology, and particularly genome-wide (whole gen-
ome or exome) sequencing, can identify genetic causes
of rare paediatric diseases much more effectively than
conventional clinical and laboratory methods [1, 2].
Furthermore, genome-wide sequencing could, at least in
theory, be used in newborn screening to identify many
more serious health conditions than is possible today
[3–8]. This possibility interests some parents [9–11],
commercial testing laboratories [12], and the US
National Institutes of Health [http://www.nih.gov/news-
events/news-releases/nih-program-explores-use-gen-
omic-sequencing-newborn-healthcare], but it also raises
serious ethical and public policy concerns [3–5, 13–20].
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Methods
The Global Alliance Paediatric Task Team developed the
recommendations shown in Table 1 for clinicians, clinical
laboratory scientists, and policy makers regarding our
current understanding, concerns and consensus regarding
the use of genomic technologies for population-based
newborn screening. This document and its recommenda-
tions were reviewed and approved by the Paediatric Task
Team in December 2015. These recommendations should
be reconsidered in the future as our knowledge in these
areas improves.
Following a brief overview of current programs and
public health policies regarding newborn screening by
other means, we describe the genomic technologies that
could be used for newborn screening and discuss how
genomic newborn screening might differ from conven-
tional newborn screening. We then consider issues of
concern related to genomic newborn screening and pro-
vide justification for each of our recommendations. We
conclude by considering the public health opportunity
genomic newborn screening offers and highlight the
need for more research in this area.
Results
Newborn screening today
Newborn screening is the process by which infants are
tested for conditions that can cause death, serious life-
long disability or chronic disease if not treated shortly
after birth. The purpose of newborn screening is to iden-
tify conditions for which effective therapy is available
and to provide this treatment early enough to prevent or
ameliorate the disease, so that affected children can live
healthier lives.
Newborn screening began in the early 1960s for in-
born errors of metabolism such as phenylketonuria
(PKU) and is now routinely performed for a variety of
conditions on almost all infants in many countries.
Given this history and wide acceptance, the essential ele-
ments of population-based newborn screening programs
have become well understood. At their heart, they are
organized approaches to early detection, through which
asymptomatic individuals in a specific population are
systematically tested for a set of conditions or for bio-
markers of the conditions. The programs aim to identify
these conditions at an early stage, generally prior to the
onset of symptoms. Screening must usually be followed
by a more definitive diagnostic process for the condition.
Once a serious condition is identified in a newborn in-
fant, treatment or management designed to ameliorate
or prevent the onset of symptoms must be initiated.
Newborn screening programs vary greatly from juris-
diction to jurisdiction with respect to which conditions
and how many diseases are tested for. Most newborn
screening is performed on a small blood sample ob-
tained by heel prick from each baby. Testing this sample
by tandem mass spectrometry, a method of identifying
and quantitating many metabolites simultaneously, per-
mits recognition of about 50 potentially treatable inborn
errors of metabolism, although most jurisdictions that
do population-based newborn screening test for only a
subset of these conditions.
Only genetic abnormalities that are associated with
major alterations of biochemicals in the blood can be
detected by tandem mass spectrometry, but other treat-
able conditions, such as congenital hypothyroidism, cystic
fibrosis, sickle cell disease, and severe combined immuno-
deficiency, can be screened in the blood spot with other
kinds of tests. A few additional disorders, such as congeni-
tal hearing loss and critical congenital heart disease, may
be screened by methods that require physical measure-
ments directly on the infant rather than analysis of a blood
sample.
Newborn screening and early diagnosis of serious disease
might seem to be advantageous under all circumstances.
Table 1 Recommendations
1. Newborn screening by any method, including genomic testing, if
adopted as a public health program should be equally available and
accessible to every infant born in the jurisdiction.
2. Interpretation of genomic newborn screening results requires
extensive knowledge of the normal (benign) variants, as well as of
pathogenic variants, of every gene tested. Genomic newborn
screening programs should, therefore, make population-specific allele
frequencies of every gene included in the program publicly available
in a freely-accessible database. The functional consequences (benign,
pathogenic, or undetermined) of each allele should also be made
available, along with the evidence supporting functional
interpretations.
3. Publicly-funded universal newborn screening by genomic methods
should be limited to diseases that can be diagnosed in the newborn
period and effectively treated or prevented in childhood.
4. If population-based genomic newborn screening is introduced, it should
only be offered as part of a comprehensive public health program that
includes appropriate confirmatory testing, therapeutic interventions,
clinical follow-up, genetic counselling, quality assurance, public and
professional education, and governance and oversight.
5. Newborn screening by next-generation sequencing or other genomic
methods should only be considered as an add-on to current first tier
screening programs.
6. Current newborn screening should not be replaced by next
generation sequencing or other genomic methods for any disease
unless the genomic technology has been shown to have equal or
better sensitivity and specificity for the disease.
7. At the present time, our understanding of, and ability to interpret
genomic variants does not justify use of genome-wide (whole genome
or exome) sequencing in population-based newborn screening. Research
is needed to demonstrate the clinical utility and cost-effectiveness of
genome-wide sequencing and to resolve outstanding health policy and
ethical issues before genome-wide sequencing is implemented for
newborn screening within a jurisdiction.
8. At the present time, our understanding of, and ability to interpret
genomic variants does not justify sequencing large multigene
(physical or bioinformatic) panels for population-based newborn
screening. Research is needed to demonstrate the clinical utility and
cost-effectiveness of sequencing large multigene panels for
population-based newborn screening and to resolve outstanding
health policy and ethical issues before the use of large sequencing
panels is implemented for newborn screening within a jurisdiction.
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However, there are several countervailing factors that must
also be considered. These include the implications of false
positive and false negative screening results; of parental
stress and anxiety about when, whether and how the dis-
ease will appear; of the often uncertain utility of available
treatments; and of the social and personal cost of the entire
program of screening and management of early or asymp-
tomatic disease.
In 1968, under the auspices of the World Health
Organization, Wilson and Jungner [21] developed cri-
teria to assess the value of potential screening programs
as public health interventions (Table 2). Almost 50 years
later, the Wilson and Jungner criteria still provide a
useful framework for assessing the value and appropri-
ateness of newborn screening programs, although some
of the criteria have been criticized and modifications
proposed in light of more recent scientific developments
and circumstances [22, 23].
Newborn screening programs follow defined protocols
to produce population-level benefits through reductions
in mortality and morbidity related to the conditions
screened. The system generally includes most, if not all,
of the following elements: Informing the family of the
testing, obtaining (or presuming) their consent, obtaining
the sample, performing the test, interpreting it, informing
the child’s physician or parents of “screen-positive” (or
“screen-negative”) results, arranging and performing con-
firmatory diagnostic testing, and initiating preventative
management or treatment, when indicated. The successful
delivery of a screening program is dependent upon effi-
cient and timely activities at each stage, delivered in line
with established policies, protocols, administration and
governance. Additional components of a successful
screening program are continuous quality management,
monitoring and evaluation. These are necessary to
demonstrate to funders, clinicians and the public that
the program is achieving its objectives, justifying the
continued investment of public resources.
Ethical and public policy issues raised by current
newborn screening practices
Population-based newborn screening with treatment or
prevention of the serious conditions identified is one of
the most successful public health interventions ever de-
vised [24–26]. Almost every baby in most developed
countries and many developing countries currently under-
goes newborn screening for various serious early-onset
diseases [27]. Introduction of genomic technology may
provide an opportunity to identify more infants for whom
early interventions can prevent serious illnesses, major
handicaps or death. However, precautions must be taken
to ensure that genomic technology is used in a manner
that does not compromise the effectiveness or societal
support of current screening programs. In order to be suc-
cessful, genomic newborn screening must learn from the
experience of conventional newborn screening over the
past 50 years. These lessons are briefly reviewed here.
Consent for newborn screening
One of the most problematic issues in population-based
newborn screening is whether parents should be asked
for permission before testing takes place. While some
programs do obtain explicit parental consent for new-
born screening, most presume consent unless the par-
ents express an objection. Such implicit consent is
justified by the belief that newborn screening is in the
child’s best interest. Newborn screening has been estab-
lished as compulsory in some jurisdictions under a pub-
lic health mandate, but even mandatory programs
usually allow parents to “opt out” if they hold religious
or other beliefs that are contrary to screening.
As programs have expanded to include conditions with
wider phenotypic variability, unclear risk associations, and
more invasive or less effective treatments, there are con-
cerns that the justification for implicit consent or
mandatory screening has been compromised [13, 28, 29].
Alternative suggestions include specific parent consent
(i.e., “opting in”) for all newborn screening or a tiered ap-
proach in which some tests would require explicit parental
consent while others would not. The tiered approach
would be designed to maintain the benefits of universal
screening for conditions where it is essential for the bene-
fit of the child while allowing parents to choose whether
or not to screen for conditions that do not meet the
standards for compulsory population-wide screening.
Unfortunately, however, a number of studies have found
poor understanding of newborn screening among parents
[13, 30–32]. This may prevent them from making
informed choices about screening if options are made
available. In addition, keeping track of and modifying the
reporting in response to varying parental requests would
greatly increase the administrative complexity and thus
the cost of a newborn screening program.
Table 2 Wilson and Jungner [21] Criteria
1. The condition sought should be an important health problem.
2. There should be an accepted treatment for patients with recognized
disease.
3. Facilities for diagnosis and treatment should be available.
4. There should be a recognizable latent or early symptomatic stage.
5. There should be a suitable test or examination.
6. The test should be acceptable to the population.
7. The natural history of the condition, including development from
latent to declared disease, should be adequately understood.
8. There should be an agreed policy on whom to treat as patients.
9. The cost of case-finding (including diagnosis and treatment of
patients diagnosed) should be economically balanced in relation to
possible expenditure on medical care as a whole.
10. Case-finding should be a continuing process and not a “once and
for all” project.
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What conditions should be screened for?
In accordance with the Wilson and Jungner criteria,
newborn screening began in all jurisdictions with condi-
tions that are life-threatening or could cause severe dis-
ability, are easy to screen for, and have an effective
treatment. In their landmark paper supporting compul-
sory PKU screening, Faden, Holtzman and Chwalow
[33] highlighted the harm that would likely occur in a
newborn infant who was not screened and argued that
this greatly outweighs the benefit of permitting parental
choice about screening. As it became possible to screen
for other conditions, similar criteria were required for
additions to the screening panel. The association of dis-
ease severity and treatability in all of the conditions
tested for provided the moral justification for making
newborn screening mandatory in many jurisdictions.
While the Wilson and Jungner criteria have generally
been used to assess the benefits and harms of adding
conditions to the screening panel, programs may inter-
pret these criteria differently and may also be subject to
different political or public pressures to add certain con-
ditions to the panel. As a consequence, different pro-
grams often screen for different conditions [34–36].
Some jurisdictions screen for fewer than ten conditions,
and others screen for more than fifty.
The potential to screen for such a large number of
conditions was made possible by the introduction of tan-
dem mass spectrometry, which permits the addition of
new screening targets to an existing metabolic panel at
almost no cost by simply adjusting the analytical soft-
ware. As a result, the kinds of conditions that have been
proposed and added to newborn screening panels in
some jurisdictions have begun to challenge conventional
ethical norms. Some of the newly added conditions are
not completely penetrant – not all infants who have the
pathogenic biomarker develop the disease. In other in-
stances, those who develop the disease may do so at a
wide range of ages, from early childhood to adulthood,
or may exhibit a wide range of disease severity or re-
sponse to treatment. In such cases, some infants who
screen positive may endure unnecessary diagnostic pro-
cedures and treatments, and their families may suffer
increased stress and anxiety as they deal with future un-
certainty. This could place a substantial burden on the
health care system, with potentially negative effects [4].
These issues are amplified if the available treatment is
expensive or associated with serious risks of adverse ef-
fects, as occurs with hematopoietic stem cell transplant-
ation, for example.
The benefits of newborn screening
Concerns have also been raised about the kinds of bene-
fits expanded newborn screening programs provide [37].
Treatment has traditionally been defined in terms of
preventing the occurrence of symptoms related to a con-
dition or substantially ameliorating those symptoms if
they do occur. In recent years, however, the concept of
“treatable” has been expanded to include reducing symp-
toms to some degree, prolonging life, or avoiding long
diagnostic quests once symptoms appear [38]. Further-
more, some advocates have pointed out that interventions
which have not been proven to be effective in reducing
morbidity or mortality might, nevertheless, benefit some
children or their families [23]. Families may also value the
opportunity to participate in disease-related research.
Cystic fibrosis, which is now screened for in many
North American, European and Australian jurisdictions,
provides an excellent example. Infants with cystic fibro-
sis rarely die or suffer irreversible damage in the new-
born period, but moderate clinical benefits have been
demonstrated in children with cystic fibrosis who are
identified by newborn screening and receive earlier
dietary and respiratory management in comparison to
children who are not diagnosed until they become symp-
tomatic [39–41].
At its core, newborn screening is intended to benefit
individual infants, but the justification for adding some
new conditions to the screening panel has been to
provide benefits beyond the infants to their families or
society. For example, providing families information
about an infant’s carrier status for a recessive genetic
disorder such as cystic fibrosis or sickle cell disease,
while of no immediate clinical benefit to the child, may
allow the parents to make future reproductive choices
that would not otherwise be available to them [42, 43].
Some have argued that reporting such findings should be
avoided because doing so increases the cost of reporting
and follow up in the screening program and has not been
shown to be beneficial [42, 44]. Others advocate informing
families of such results, which are produced incidentally
by screening for primary targets with methods like tandem
mass spectrometry or high-performance liquid chroma-
tography of hemoglobin [45–47]. While expanding the
scope of benefits considered may not be unethical, it does
represent a shift in the goals of newborn screening that
necessitates re-examination of its ethical justification.
Secondary use of newborn screening blood spots
Another issue that has raised controversy in several
jurisdictions is retention and secondary use of leftover
dried blood spots after newborn screening is complete.
Residual blood spots are routinely used for internal
laboratory quality assurance purposes and confirmation
of original results [48]. In addition, the residual blood
spots may be used to refine current methodologies and
to develop new newborn screening tests [49]. These uses
are generally accepted because they are related to the
primary purpose of the blood collection [50, 51].
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As blood spots are collected from almost all children
at the time of birth, these samples also represent a
unique population-based resource for biomedical re-
search, public health surveillance, and forensic uses,
such as the identification of disaster victims [52–55].
Biomedical and public health research using stored
blood spots has contributed to our understanding in sev-
eral important areas [56], including the development of
childhood leukemia [57] and whether pregnant women
are eating fish that contain excessive amounts of mer-
cury [55]. However, the lack of consent from the parents
for such uses is problematic, especially for programs that
do not obtain consent for screening itself. As a conse-
quence, policies regarding the retention and secondary
use of newborn screening blood spots vary greatly
worldwide [54, 55, 58–60] and secondary use of such
blood spots has been the subject of several lawsuits in
the United States and Canada [54].
Genetic testing in newborn screening
Testing for mutations of individual genes and sets of genes
Many potentially treatable conditions cannot be detected
in infants using current newborn screening methods
[61]. Most of these disorders result from genetic muta-
tions (either inherited from one or both of the parents
or arising de novo in the child) and could, in principle,
be diagnosed shortly after birth by means of available
genomic technologies [4, 62, 63]. Examples include
many early-onset seizure disorders, cardiac arrhythmias,
cardiomyopathies, diseases of the blood or bone marrow,
liver diseases and kidney disorders.
Clinical laboratories currently employ molecular gen-
etic technologies for a variety of purposes, including the
identification of bacteria or viruses involved in a pa-
tient’s infection and matching tissue antigens between a
donor organ and a patient who requires organ trans-
plantation. In addition, genetic testing is routinely per-
formed by clinical labs in circumstances other than
newborn screening – for example, to screen pregnant
women for fetal Down syndrome [64–66] or in critically
ill intensive care unit patients suspected of having a gen-
etic disease. The latter approach has been successfully
applied to newborn infants [67, 68], but it is important
to distinguish this use of genome-wide sequencing for
rapid diagnosis in a small number of critically ill infants
from population-based newborn screening, where almost
all babies, including those who are completely healthy,
are tested [69].
There are several different kinds of genetic tests that
could be used in newborn screening. Some employ
conventional technologies; other tests are performed
with massively-parallel (“next-generation”) sequencing
machines, which, in comparison to the sequencers used
in the Human Genome Project, produce 8,000,000 times
more data 24,000 times faster at a cost that is 3,000,000
times lower [70–72]. Genetic tests include:
1. Molecular genetic testing by methods that do not
involve sequencing, e.g., PCR of specific genetic
targets. Such methods have been used in diagnostic
testing for many years and are the clinical standard
for rapid identification of infectious agents [73, 74].
A PCR-based technique has recently been adopted
in some jurisdictions to screen newborn infants for
severe combined immunodeficiency disease [75], a
group of genetic disorders causing recurrent and
eventually lethal infections that can be effectively
treated by early stem cell transplantation. Simple
molecular analytic technologies are also used to
identify disease-causing germ-line mutations for
confirmatory testing in some newborn screening
programs [4] and even for primary screening in a
few instances in which one or two specific mutations
are responsible for almost all cases of a disease
within a particular population. One example is
newborn screening for glutaric acidemia type 1 caused
by homozygosity for the GCDH, IVS1, G-T, +5
mutation in the Canadian province of Manitoba [76].
2. Sequencing individual genes. For more than 25 years,
clinical laboratories have offered sequencing of
individual genes, such as those for cystic fibrosis
(CFTR) or Duchenne muscular dystrophy (DMD), to
provide a molecular diagnosis in affected individuals.
This testing is usually done by conventional (Sanger)
sequencing of PCR-amplified coding regions of the
gene. Individual gene sequencing is useful for clinical
diagnosis in patients of any age, including newborn
infants, but is too expensive and not sufficiently
automatable to use for population-based screening.
However, sequencing individual genes is used in
some newborn screening programs for secondary or
confirmatory testing of screen-positive infants [77–79].
3. Gene panels. Gene panels are sets of genes that are
sequenced as a group. The group is selected because
mutations of any of the included genes can produce
clinically similar disease or, more broadly, diseases of
the same class. The first panels offered for clinical
diagnosis were small – three genes (F8, F9 and
VWF) for a coagulation disorder, for example – in
essence just a few single gene tests done together.
More recently, larger and larger gene panels have
been developed, and it is now possible to obtain
panels that test simultaneously for mutations in
hundreds of genes associated with epilepsy or
intellectual disability, or even for any of more than
3000 genes associated with mendelian diseases [80].
As the panels have grown larger, the technology
employed has changed, with larger panels using
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higher through-put methods to capture the coding
segments of the genes that are being tested, next
generation methods for sequencing, and additional
studies to look for mutations like genomic copy
number changes that are difficult to identify by
sequencing. Some laboratories offer “bioinformatic
panels” that involve sequencing the coding regions
of all genes (exome sequencing) but analyzing and
reporting on only a selected subset of those genes.
Genome-wide (Whole genome or exome) sequencing
With the development of next-generation DNA sequen-
cing technology and its substantial reduction in cost
over recent years, sequencing all of the DNA (the whole
genome) or the coding segments of all of the genes (the
exome) in the cells of an individual all at once has
emerged as a robust method of identifying mutations
that cause treatment-resistant cancer [81, 82] or any of
thousands of serious genetic conditions in patients with
previously undiagnosed diseases [1, 83–88].
Most clinical laboratories currently utilize a different
method, usually Sanger sequencing, to confirm patho-
genic variants identified by genome-wide sequencing.
However, clinical validity – whether recognizing disease-
associated variants by sequencing (e.g., of the CFTR
locus) predicts the disease (e.g., cystic fibrosis) – is often
a more difficult question to resolve than analytical valid-
ity. No systematic studies of the clinical validity of
genome-wide sequencing are available, but false positive
and false negative reports of pathogenic variants are
known to occur [1, 89, 90]. Such errors are more likely
in circumstances like newborn screening, where the a
priori chance that an individual will have any particular
rare genetic disease is vanishingly small. Moreover, rigor-
ous genotype-phenotype correlation, which is critical for
clinical interpretation of genomic variants [91, 92], is
impossible in most existing screening programs because
information about illness or birth defects in the infants
is not available to the screening laboratory.
Novel ethical and policy issues raised by genome-wide
sequencing
All of the ethical and public policy issues associated with
current newborn screening practices apply to genome-
wide sequencing as well, and many of these issues are
exacerbated by the fact that genome-wide sequencing
produces much more information about the individual
than conventional testing does. For example, it is more
difficult (or impossible) to justify mandatory screening,
even if families have the ability to opt out, if many add-
itional screening targets are added, especially if the bene-
fits of screening for some of these additional targets are
uncertain. At the very least, genomic newborn screening
would require ensuring that parents have sufficient,
clearly-understandable information available about the
screening program and that the entire population has
access to confirmatory diagnostic and treatment services,
including genetic counselling. Maintaining effective gov-
ernance and efficient administration of population-based
genomic newborn screening programs would also be
essential to avoid losing the high participation rates
and widespread public support that these programs
currently enjoy.
Interpretation of genomic newborn screening results
The biggest challenge to using genome-wide sequencing
to diagnose genetic disease is interpretation of the results
[91, 93, 94]. The pathogenicity of genetic variants is often
difficult to infer, especially if they are very rare or novel, as
may often occur in general population screening. Rigorous
criteria have been developed to define pathogenicity for
clinical diagnostic labs, and the interpretation of variants
is greatly aided by the accumulation of large databases of
established pathogenic or benign variants [95, 96]. Never-
theless, some variants cannot be classified as either patho-
genic or benign and must be reported as variants of
uncertain significance (VUS), which can cause concern
(often, but not always, unnecessarily) for individuals or
families. In sick children who undergo diagnostic sequen-
cing, the clinical phenotype can be used to help determine
whether a variant is likely to be pathogenic by comparing
the child’s phenotype to that expected if the variant were
pathogenic. In contrast, the purpose of newborn screening
is to identify infants with serious disorders before they be-
come clinically apparent, and if the phenotype has not yet
developed, it cannot be used to determine the pathogen-
icity of a genetic variant [1].
Return of genome-wide sequencing results The uncer-
tainty about interpretation raises questions regarding
which variants laboratories should report back to clinicians
and, in turn, to what extent there is an obligation to com-
municate these findings back to the patient [20, 97–100].
The resources required to investigate and communicate
these findings may be a substantial burden on the health
care system [3]. Other concerns include the potential for
psychological harm to patients and their families, and the
legal implications for laboratories and clinicians [101].
An additional complexity with genomic newborn
screening relates to the fact that the testing is performed
on infants who are legally incompetent when screened
but who will gain competence when they grow older.
This situation is not limited to newborn screening, of
course – infants and young children are incompetent to
make any decision regarding medical treatment or
health screening. However, genomic newborn screening
could detect diseases or predispositions to disease that
do not have onset until middle or late adulthood, and
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we know that many adults choose not to have genetic
testing for such conditions when it is offered [102–105].
Allowing substitute decision makers (usually the par-
ents) to make decisions about such testing in infants
raises issues relating to respect for future autonomy and
privacy protection.
Genomic incidental findings A major consideration if
genome-wide (or large gene panel) sequencing were to be
used for newborn screening is the frequent occurrence of
“incidental findings” – genetic variants of potential im-
portance to the child or family that are unrelated to the
diseases for which the testing is performed [17, 106–110].
The use of the term “incidental” to describe these findings
suggests that they are inadvertently found during the ana-
lysis of genomic data. This can and does happen, but it is
also possible to look actively for genomic variants beyond
those for which the screening is being performed. Variants
of such secondary targets are sometimes called “secondary
findings”. Others have used the terms “unsolicited”,
“unanticipated”, or “adventitious” to describe incidental
and/or secondary findings.
The frequency with which incidental or secondary
findings are encountered can range from a few percent
of patients to every single individual tested, depending
on how the data are analyzed and what kinds of findings
the testing laboratory reports. Even at the lowest fre-
quency reported for genome-wide sequencing, incidental
findings would be expected to occur more frequently
than true positive results for disease-causing mutations
associated with any of the rare genetic diseases tested
for by conventional newborn screening.
Return of incidental findings that arise in diagnostic
genome-wide sequencing is a contentious issue, and one
that has elicited a number of sometimes-conflicting pol-
icy recommendations [4, 9, 17, 56, 97, 98, 101, 111, 112].
Areas of concern include the kinds of incidental or sec-
ondary findings that should be returned – should these
only include “actionable” findings (i.e., those diagnostic
of a condition for which an effective preventative or
therapeutic intervention is available) or should findings
that cannot be effectively prevented or treated also be
returned? What about findings related to small or mod-
erately increased risks of diseases that are common in
the general population, or findings that may or may not
be of value, depending on circumstances (e.g., pharma-
cogenetic variants or carrier status for recessive dis-
eases)? Should patients be able to obtain results that are
irrelevant medically but may have social importance
(e.g., ancestry, potential for athletic performance, or gen-
etic sex that differs from gender)?
Controversy has also arisen over which considerations
should be prioritized with respect to the return of re-
sults. Should the focus be on returning any finding that
could possibly be of benefit to an individual patient, or
should incidental findings never be returned to maximize
the cost-effectiveness of diagnosing serious diseases in the
population as a whole? Should incidental findings only be
returned if specifically requested by the patient (or their
parents, if the patient is a child), or should such findings
always be returned unless specifically declined? Return of
information that is of no immediate benefit to a child but
may be of benefit to other family members (e.g., the pres-
ence of pathogenic BRCA1 mutation for hereditary breast
and ovarian cancer in a little boy so that his mother can
be tested for the mutation) is particularly contentious be-
cause it violates a core ethical principle that medical pro-
cedures in children are only justifiable if they directly
benefit the child [101, 113].
In the context of population screening of infants, the
ethical and policy concerns raised by return of incidental
genomic findings are, if anything, even greater than for
diagnostic genome-wide sequencing. Some have even
questioned whether decisions about return of genomic in-
formation uncovered during newborn screening should be
made by public health officials or policy-makers at all,
arguing that all genomic data belong to the child, and that
the parents, who are presumed to act most effectively in
the child’s best interests, should decide what is of import-
ance and what is not [114–117].
Storage of personal genomic data As previously men-
tioned, storage and secondary use of infant blood spots
obtained for population-based newborn screening is con-
tentious, and similar issues arise for DNA samples isolated
from these blood spots for genomic testing. Moreover,
genome-wide sequencing would produce a large amount
of information on each infant that is both potentially iden-
tifying and revealing of important medical or social issues.
What should be done with these data once the newborn
screening has been completed has generated substantial
discussion. Some argue that a child could benefit from this
information being stored in his or her electronic patient
record for tailoring medical treatments to particular dis-
eases that may arise later in life [3, 17]. These data would
also provide very valuable research opportunities in areas
such as population genetics, genome-wide association
studies, penetrance of genetic disorders, and genotype-
phenotype correlations [99].
The cost, risks and benefits of long-term storage of
genomic data depend greatly on what is being stored
and how it is stored. At one extreme, only the highest
level results of newborn screening might be stored, e.g.,
“no cystic fibrosis-associated CFTR allele found”, while
at the other extreme a complete list of all variants or
each individual’s entire exome or whole genome
sequence might be stored. The former does not differ
from the storage of any other medical result in a health
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record, while the latter provides the greatest amount of
both potentially beneficial and potentially harmful infor-
mation. Moreover, storage of raw genome sequence
would be of very little value without the ability to extract
useful clinical information from it as needed and to re-
turn this information to the patient, family or physician
in an appropriate manner. The cost of doing this is likely
to remain far greater than the cost of data storage for
the foreseeable future [16].
Others argue that the cost of secure storage and stew-
ardship of these data over the lifetime of the child may
exceed the cost of repeating the genomic testing in the
future if the information becomes necessary [17]. The
possibility of misusing this information for discrimin-
atory purposes, for example, with regard to employment
or insurance, is particularly concerning and must be pre-
vented [3, 4, 118]. The balance struck between the bene-
fits, risks and costs of storing individual data obtained
through any genomic newborn screening program is
likely to vary among jurisdictions in response to societal
and political forces as well as factors like cost and avail-
able public health infrastructure.
Discussion
Recommendations – further improving public health
Genomic technology provides an opportunity to improve
newborn screening by identifying more infants for whom
early interventions can prevent serious illnesses, major
handicaps or death. However, to be successful, genomic
newborn screening must avoid compromising the effect-
iveness of current screening programs or inadvertently
harming children and their families. We, therefore, make
eight recommendations regarding the use of genomic
technologies for population-based newborn screening.
We consider Recommendations 1-4 to be fundamental
and independent of the specific genomic technology
used. Recommendations 5-8 are precautionary and relate
to the current state of available genomic testing
methods. These recommendations should be reconsid-
ered from time to time in the future as our knowledge
improves.
Recommendation 1: Newborn screening by any method,
including genomic testing, if adopted as a public health
program should be equally available and accessible to
every infant born in the jurisdiction.
The success of current newborn screening programs is
largely a reflection of their provision to all, or nearly all,
infants. This population-based coverage, which will also
be essential for effective genomic newborn screening, re-
quires universal access for all babies. This is a principle
of public health as well as a matter of justice.
Recommendation 2: Interpretation of genomic newborn
screening results requires extensive knowledge of the nor-
mal (benign) variants, as well as of pathogenic variants,
of every gene tested. Genomic newborn screening programs
should, therefore, make population-specific allele fre-
quencies of every gene included in the program publicly
available in a freely-accessible database. The functional
consequences (benign, pathogenic, or undetermined) of
each allele should also be made available, along with the
evidence supporting functional interpretations.
Because the diseases that are screened for in newborns
are rare (or extremely rare) and because the frequencies
of benign polymorphisms, VUS, and disease-causing
mutations differ in different ethnic, cultural or geo-
graphic populations, sharing information on the patho-
genicity of variants internationally in a freely-accessible
database will be essential for interpretation of genomic
screening results [119, 120]. This must, of course, be
done in a way that protects the privacy of individual in-
fants and their families appropriately [121]. Privacy pro-
tection is easily managed for common benign variants,
which only need to be reported as frequencies (e.g., “327
per 10,000 in Southern Han Chinese populations”) but
may be more difficult for disease-causing variants that
are so rare that their occurrence in a particular popula-
tion is limited to one individual or family. In such
instances, the individual’s or family’s consent may be
necessary for posting the information in a publicly-
accessible database, but we believe that most affected
families will agree to this to benefit other affected
families.
Recommendation 3: Publicly-funded universal newborn
screening by genomic methods should be limited to
diseases that can be diagnosed in the newborn period
and effectively treated or prevented in childhood.
In public health programs, limited funding is available
and prioritization is required. Unless the screening process
for a condition is robust and cost effective, its inclusion in
a newborn screening program is more likely to be harmful
than beneficial to the performance of the program as a
whole. The cost of genome sequencing has fallen dramat-
ically over past 15 years and is likely to continue to fall as
a result of ongoing technical advances. Nevertheless, the
cost of genome-wide (whole genome or exome) sequen-
cing remains at least 10-100 times greater than any
current publicly-funded newborn screening program.
Moreover, the sensitivity and specificity of sequencing
technology and analytical pipelines have not been shown
to be (and are currently probably not) sufficiently high for
use in population-based screening [7].
Unless an effective preventative or therapeutic inter-
vention is available to all children who are diagnosed
with a condition that is screened for, the program is un-
likely to benefit the infants who are being screened in a
manner that can be demonstrated to funding agencies.
Publicly-funded newborn screening programs, like all
public health programs, are held to a high standard of
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accountability, and if genomic newborn screening com-
promised the cost-benefit calculation for the screening
program as a whole, current newborn screening activ-
ities, which have been highly beneficial to many children,
could be jeopardized.
Recommendation 4: If population-based genomic new-
born screening is introduced, it should only be offered as
part of a comprehensive public health program that in-
cludes appropriate confirmatory testing, therapeutic inter-
ventions, clinical follow-up, genetic counselling, quality
assurance, public and professional education, and govern-
ance and oversight.
As discussed above, the success of current newborn
screening programs depends on systematic screening,
diagnosis, and management of affected infants through
established policies and protocols. Efficient administration
and effective governance are also necessary, along with
ongoing monitoring and evaluation. Genomic newborn
screening would probably be more complex than current
screening programs and would, therefore, need to build
on the strengths of current programs and operate as a
comprehensive system that is available to every infant.
Recommendation 5: Newborn screening by next-
generation sequencing or other genomic methods should
only be considered as an add-on to current first-tier
screening programs.
Recommendation 6: Current newborn screening should
not be replaced by next generation sequencing or other
genomic methods for any disease unless the genomic tech-
nology has been shown to have equal or better sensitivity
and specificity for the disease.
These recommendations are consistent with the
Wilson and Jungner criteria (Table 2) and more recent
analyses of their application to genome screening at its
current state of development for clinical testing [22, 122].
Some conditions for which newborn screening is widely
performed cannot be identified effectively by any method
of genetic or genomic testing because many cases do not
have a genetic cause. For example, congenital hypo-
thyroidism may be caused by maternal dietary iodine defi-
ciency or transfer of maternal anti-thyroid antibodies
across the placenta. In other circumstances, even though
genetic factors usually cause the condition, genetic hetero-
geneity and complexity make it unlikely that genetic test-
ing will be as sensitive or as specific as current screening
methods. Newborn screening for congenital hearing loss
by testing otoacoustic emissions provides a clear example.
Substituting genomic methods for the methods that are
currently used to screen for such conditions would
jeopardize the health or development of some children who
are identified by current newborn screening programs.
Even for conditions in which genetic heterogeneity
and complexity are of less concern, genomic testing may
not currently be the most robust method for population-
based newborn screening. Bodian and associates studied
1696 infants who had undergone whole genome sequen-
cing and conventional newborn screening in a state-
sponsored program [7]. Whole genome sequencing data
from these infants were analysed for possible disease-
causing variants of 163 genes involved in diseases that
either are routinely tested or are being considered for
testing in American newborn screening programs. The
average infant in this study carried one variant detected
by sequencing that was annotated as pathogenic
(median = 1, range 0-6). The state newborn screening
program identified 4 of 5 infants with a currently
targeted disease, while whole genome sequencing identi-
fied only 2 of these 5 infants. Among the 27 diseases
(associated with 65 genes) tested for in the state newborn
screen program, there were fewer false positive results but
more results of uncertain clinical significance with whole
genome sequencing.
Genomic methods such as next-generation sequencing
could, at least in theory, detect some infants with poten-
tially treatable early-onset genetic conditions that are not
currently being identified by newborn screening [3–8].
The addition of such conditions to the newborn screening
panel may be beneficial and cost-effective, but research is
required to demonstrate that this is true.
Recommendation 7: At the present time, our under-
standing of, and ability to interpret genomic variants
does not justify use of genome-wide (whole genome or
exome) sequencing in population-based newborn screening.
Research is needed to demonstrate the clinical utility and
cost-effectiveness of genome-wide sequencing and to resolve
outstanding health policy and ethical issues before
genome-wide sequencing is implemented for newborn
screening within a jurisdiction.
The diploid human genome consists of more than
6,000,000 base pairs of DNA, and every person has mil-
lions of differences in comparison to the human refer-
ence sequence. Some of these variants are known to be
benign, occurring as frequent polymorphisms in healthy
individuals. Other variants are known or very likely to
cause genetic disease. Many other variants cannot be
classified as being benign or disease-causing; genome-
wide sequencing identifies many such VUS in every indi-
vidual [123, 124]. A typical exome from a person who
does not have a mendelian disease includes more than
100 novel or rare variants that are predicted to alter
protein function [123, 124]. Clinical diagnosis of a genetic
disease from genome-wide sequencing data requires
recognition of the one or two variants that actually cause
the disease in this large background of other variants that
are present but have nothing to do with the condition.
As discussed above, interpretation of genomic sequen-
cing results is the biggest practical problem in using this
methodology for population screening of newborn
Friedman et al. BMC Medical Genomics  (2017) 10:9 Page 9 of 13
infants [91, 93, 94]. The high-throughput sequencing
and bioinformatics infrastructure and expertise required
to interpret exome or whole genome data from many
thousands of infants each year are beyond the capacity
of current publicly-funded programs and would be very
costly to put into place. Moreover, even when a genomic
variant can be interpreted with certainty as pathogenic,
predicting the resulting phenotype may be difficult.
Different mutations of a single genetic locus can cause
different diseases, and identical mutations in different
individuals can cause disease manifestations of strikingly
different severity.
It is often difficult to obtain the evidence of cost-
effectiveness and therapeutic efficacy needed to justify
the addition of one condition to the newborn screening
panel. The rarity of genetic diseases in infants frequently
confounds rigorous cost-benefit analysis and makes ran-
domized controlled trials of the efficacy of therapeutic
interventions infeasible. It is hard to imagine how such
data could be collected for all genetic diseases that
might be identified by genome-wide sequencing, and
obtaining these data just for the conditions covered by a
large gene panel would pose immense problems.
Thorough assessment of the success of initial efforts at
population-based genomic newborn sequencing will
certainly be necessary.
Recommendation 8: At the present time, our under-
standing of, and ability to interpret genomic variants
does not justify sequencing large multigene (physical or
bioinformatic) panels for population-based newborn
screening. Research is needed to demonstrate the clinical
utility and cost-effectiveness of sequencing large multi-
gene panels for population-based newborn screening and
to resolve outstanding health policy and ethical issues
before the use of large sequencing panels is implemented
for newborn screening within a jurisdiction.
Most current suggestions for expanding newborn
screening through sequencing of disease genes propose
to do so by using targeted panels [17, 125]. Interpret-
ation of variants found on gene panels with respect to
pathogenicity presents the same difficulties as interpret-
ation of the variants found by sequencing individual
genes but multiplies these problems by as many genes as
there are on the panel. Although sequencing a small
panel of genes is much less likely than genome-wide
sequencing to produce incidental findings or VUS, these
issues are unlikely to be completely resolved, and the
advantages are lost as the gene panel becomes larger
[4, 99]. The more genes included in the panel, the larger
the proportion of variants for which the association with
disease is uncertain. The penetrance, variability and
natural history of disease caused by particular mutations
become more uncertain as the number of genes on a
panel increases, and the frequency and distribution of
benign polymorphisms in various populations is more
often unknown.
In any case, we do not currently know enough about
the pathogenic consequences of the full population
spectrum of variants for any disease gene, and much less
for a panel of disease genes, to justify the use of such se-
quencing as a primary method of newborn screening.
More research in this area is needed.
Conclusions
The inclusion of genomic sequencing in newborn
screening presents a major opportunity to detect and ef-
fectively treat or prevent many more serious child health
conditions than is possible today. However, before gen-
omic sequencing can be implemented in a newborn
screening program, clinical utility and cost-effectiveness
must be demonstrated [37, 110, 111]. A key issue is the
need to improve the interpretation of genomic data to
permit robust recognition of both disease-causing and
benign variants of all genes screened in every child in
the population. In addition, a consensus needs to be
developed within each jurisdiction on ethical and policy
controversies such as the disclosure of genomic VUS
and incidental findings to families, ownership of the
data, and appropriate data storage and sharing. Revision
of our recommendations will be needed as more infor-
mation becomes available.
The best interests of children should remain the
guiding principle in newborn screening and the basis for
decisions regarding the implementation of genomic
newborn screening.
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